This blog was written in conjunction with Kavita Nanda of FHI 360 and originally posted here on the K4Health website. It is republished here with permission. Disclaimer: Dr. Nanda and I were both directly involved in work on the 2014 WHO HC-HIV guidance and the USAID/PEPFAR briefer on hormonal contraception and antiretroviral medications.
Among all people living with HIV in low- and middle-income countries, 52% are women (57% in sub-Saharan Africa). Most are of reproductive age, and many may wish to use a hormonal contraceptive method to prevent unintended pregnancy, such as oral contraceptive pills, injectables, implants, or hormonal intrauterine devices (IUDs). Access to highly effective contraception has other health benefits as well; it reduces maternal and infant morbidity and mortality, and is a necessary component in ending mother-to-child HIV transmission.
Therefore, an increasingly important issue is whether certain ART regimens are expected to have drug interactions when used with certain hormonal contraceptive methods.